UA81118C2 - N-((3-oxo-2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris - Google Patents

Info

Publication number

UA81118C2

UA81118C2 UA20041211001A UA20041211001A UA81118C2 UA 81118 C2 UA81118 C2 UA 81118C2 UA 20041211001 A UA20041211001 A UA 20041211001A UA 20041211001 A UA20041211001 A UA 20041211001A UA 81118 C2 UA81118 C2 UA 81118C2

Authority

UA

Ukraine

Prior art keywords

oxo

dihydro

isoindol

isobutyl

carbon atoms

Prior art date

2002-06-03

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims abstract description 63
• 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 6
• 206010061216 Infarction Diseases 0.000 title abstract 3
• 230000007574 infarction Effects 0.000 title abstract 3
• 239000003112 inhibitor Substances 0.000 title description 39
• MGRUNSIBUNAFKA-UHFFFAOYSA-N n-(diaminomethylidene)-2-(3-oxo-1,2-dihydroisoindol-1-yl)acetamide Chemical class C1=CC=C2C(CC(=O)NC(=N)N)NC(=O)C2=C1 MGRUNSIBUNAFKA-UHFFFAOYSA-N 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 125
• 238000000034 method Methods 0.000 claims abstract description 104
• 239000003814 drug Substances 0.000 claims abstract description 31
• 208000028867 ischemia Diseases 0.000 claims abstract description 15
• 206010019280 Heart failures Diseases 0.000 claims abstract description 14
• 238000002360 preparation method Methods 0.000 claims abstract description 10
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
• 206010003119 arrhythmia Diseases 0.000 claims abstract description 6
• 239000000203 mixture Substances 0.000 claims description 265
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 218
• 230000002829 reductive effect Effects 0.000 claims description 165
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 142
• -1 MKakr Chemical group 0.000 claims description 112
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 109
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 109
• 125000004432 carbon atom Chemical group C* 0.000 claims description 99
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 85
• 150000003839 salts Chemical class 0.000 claims description 65
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
• 230000002265 prevention Effects 0.000 claims description 44
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 42
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 42
• 101100184238 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MNE1 gene Proteins 0.000 claims description 41
• 125000000217 alkyl group Chemical group 0.000 claims description 33
• 208000035475 disorder Diseases 0.000 claims description 31
• 229940126601 medicinal product Drugs 0.000 claims description 30
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 27
• 239000001257 hydrogen Substances 0.000 claims description 26
• 229910052739 hydrogen Inorganic materials 0.000 claims description 26
• 229940079593 drug Drugs 0.000 claims description 23
• 239000004480 active ingredient Substances 0.000 claims description 22
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 19
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
• 210000002216 heart Anatomy 0.000 claims description 18
• 230000003993 interaction Effects 0.000 claims description 17
• 210000000056 organ Anatomy 0.000 claims description 17
• 230000001154 acute effect Effects 0.000 claims description 12
• 201000010099 disease Diseases 0.000 claims description 12
• 125000001072 heteroaryl group Chemical group 0.000 claims description 11
• 229910052740 iodine Inorganic materials 0.000 claims description 11
• 201000001320 Atherosclerosis Diseases 0.000 claims description 10
• 125000003118 aryl group Chemical group 0.000 claims description 10
• 210000003169 central nervous system Anatomy 0.000 claims description 10
• 208000010125 myocardial infarction Diseases 0.000 claims description 10
• 210000001519 tissue Anatomy 0.000 claims description 10
• 125000003545 alkoxy group Chemical group 0.000 claims description 9
• 230000000302 ischemic effect Effects 0.000 claims description 9
• 206010048554 Endothelial dysfunction Diseases 0.000 claims description 8
• 206010020772 Hypertension Diseases 0.000 claims description 8
• 230000032683 aging Effects 0.000 claims description 8
• 206010012601 diabetes mellitus Diseases 0.000 claims description 8
• 230000008694 endothelial dysfunction Effects 0.000 claims description 8
• 230000010410 reperfusion Effects 0.000 claims description 8
• 125000001424 substituent group Chemical group 0.000 claims description 8
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
• 208000007536 Thrombosis Diseases 0.000 claims description 7
• 125000003282 alkyl amino group Chemical group 0.000 claims description 7
• 230000001472 cytotoxic effect Effects 0.000 claims description 7
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 7
• 230000035939 shock Effects 0.000 claims description 7
• 208000017667 Chronic Disease Diseases 0.000 claims description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
• 150000001412 amines Chemical class 0.000 claims description 6
• 230000001451 cardiotoxic effect Effects 0.000 claims description 6
• 230000004663 cell proliferation Effects 0.000 claims description 6
• 231100000433 cytotoxic Toxicity 0.000 claims description 6
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 5
• 125000005842 heteroatom Chemical group 0.000 claims description 5
• 229910052757 nitrogen Inorganic materials 0.000 claims description 5
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
• 230000002093 peripheral effect Effects 0.000 claims description 5
• XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 5
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
• KWKPPZVLRABURT-UHFFFAOYSA-N 1-ethoxyethenoxy(trimethyl)silane Chemical group CCOC(=C)O[Si](C)(C)C KWKPPZVLRABURT-UHFFFAOYSA-N 0.000 claims description 4
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
• 206010027476 Metastases Diseases 0.000 claims description 4
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
• 231100000457 cardiotoxic Toxicity 0.000 claims description 4
• 239000003153 chemical reaction reagent Substances 0.000 claims description 4
• 230000003176 fibrotic effect Effects 0.000 claims description 4
• 125000000623 heterocyclic group Chemical group 0.000 claims description 4
• 230000009401 metastasis Effects 0.000 claims description 4
• 206010001497 Agitation Diseases 0.000 claims description 3
• 208000019901 Anxiety disease Diseases 0.000 claims description 3
• 208000003495 Coccidiosis Diseases 0.000 claims description 3
• 208000007530 Essential hypertension Diseases 0.000 claims description 3
• 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
• 206010020880 Hypertrophy Diseases 0.000 claims description 3
• 206010022562 Intermittent claudication Diseases 0.000 claims description 3
• 206010023076 Isosporiasis Diseases 0.000 claims description 3
• 239000002841 Lewis acid Substances 0.000 claims description 3
• 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
• 150000004791 alkyl magnesium halides Chemical class 0.000 claims description 3
• 230000006793 arrhythmia Effects 0.000 claims description 3
• 230000001580 bacterial effect Effects 0.000 claims description 3
• 150000001718 carbodiimides Chemical class 0.000 claims description 3
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
• 230000006806 disease prevention Effects 0.000 claims description 3
• 150000004678 hydrides Chemical class 0.000 claims description 3
• 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
• 150000007517 lewis acids Chemical class 0.000 claims description 3
• 201000004792 malaria Diseases 0.000 claims description 3
• 244000144977 poultry Species 0.000 claims description 3
• 210000002307 prostate Anatomy 0.000 claims description 3
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
• 238000003860 storage Methods 0.000 claims description 3
• 208000005057 thyrotoxicosis Diseases 0.000 claims description 3
• 238000002054 transplantation Methods 0.000 claims description 3
• 230000002792 vascular Effects 0.000 claims description 3
• 125000003342 alkenyl group Chemical group 0.000 claims description 2
• 125000000304 alkynyl group Chemical group 0.000 claims description 2
• 206010020718 hyperplasia Diseases 0.000 claims description 2
• NRUBUZBAZRTHHX-UHFFFAOYSA-N lithium;propan-2-ylazanide Chemical compound [Li+].CC(C)[NH-] NRUBUZBAZRTHHX-UHFFFAOYSA-N 0.000 claims description 2
• 201000004240 prostatic hypertrophy Diseases 0.000 claims description 2
• 150000002431 hydrogen Chemical class 0.000 claims 10
• 206010016654 Fibrosis Diseases 0.000 claims 4
• 230000004761 fibrosis Effects 0.000 claims 4
• 208000003663 ventricular fibrillation Diseases 0.000 claims 3
• 206010002199 Anaphylactic shock Diseases 0.000 claims 2
• 206010010904 Convulsion Diseases 0.000 claims 2
• 206010021138 Hypovolaemic shock Diseases 0.000 claims 2
• 206010023421 Kidney fibrosis Diseases 0.000 claims 2
• 208000028017 Psychotic disease Diseases 0.000 claims 2
• 231100000504 carcinogenesis Toxicity 0.000 claims 2
• 206010007625 cardiogenic shock Diseases 0.000 claims 2
• 208000037976 chronic inflammation Diseases 0.000 claims 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
• 230000036461 convulsion Effects 0.000 claims 2
• 206010015037 epilepsy Diseases 0.000 claims 2
• 230000037356 lipid metabolism Effects 0.000 claims 2
• 206010040560 shock Diseases 0.000 claims 2
• 210000001835 viscera Anatomy 0.000 claims 2
• 208000020401 Depressive disease Diseases 0.000 claims 1
• 230000003712 anti-aging effect Effects 0.000 claims 1
• 230000036506 anxiety Effects 0.000 claims 1
• 208000015114 central nervous system disease Diseases 0.000 claims 1
• 208000019622 heart disease Diseases 0.000 claims 1
• 208000030175 lameness Diseases 0.000 claims 1
• 210000001428 peripheral nervous system Anatomy 0.000 claims 1
• 239000002831 pharmacologic agent Substances 0.000 claims 1
• 229910052698 phosphorus Inorganic materials 0.000 claims 1
• 238000012876 topography Methods 0.000 claims 1
• 238000011161 development Methods 0.000 abstract description 5
• XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 abstract description 5
• 230000006378 damage Effects 0.000 abstract description 4
• 230000008569 process Effects 0.000 abstract description 4
• 239000003416 antiarrhythmic agent Substances 0.000 abstract description 3
• 230000003293 cardioprotective effect Effects 0.000 abstract description 3
• 230000035778 pathophysiological process Effects 0.000 abstract description 3
• 230000003449 preventive effect Effects 0.000 abstract description 2
• 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
• 239000000543 intermediate Substances 0.000 abstract 1
• 238000011321 prophylaxis Methods 0.000 abstract 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 399
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 207
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 126
• 239000000047 product Substances 0.000 description 118
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 111
• 239000011541 reaction mixture Substances 0.000 description 108
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 97
• 239000007787 solid Substances 0.000 description 92
• 239000000741 silica gel Substances 0.000 description 91
• 229910002027 silica gel Inorganic materials 0.000 description 91
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 90
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
• 239000000243 solution Substances 0.000 description 84
• 229960004198 guanidine Drugs 0.000 description 77
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 65
• 239000003480 eluent Substances 0.000 description 63
• 238000004809 thin layer chromatography Methods 0.000 description 59
• 238000004587 chromatography analysis Methods 0.000 description 55
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 53
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 50
• 239000002904 solvent Substances 0.000 description 48
• 239000000284 extract Substances 0.000 description 45
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 45
• 235000019341 magnesium sulphate Nutrition 0.000 description 45
• 238000004128 high performance liquid chromatography Methods 0.000 description 42
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 37
• 229920006395 saturated elastomer Polymers 0.000 description 37
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 36
• 239000008346 aqueous phase Substances 0.000 description 34
• 239000003921 oil Substances 0.000 description 32
• 235000019198 oils Nutrition 0.000 description 32
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
• 239000002245 particle Substances 0.000 description 29
• 239000000843 powder Substances 0.000 description 28
• 229910052786 argon Inorganic materials 0.000 description 25
• 239000000126 substance Substances 0.000 description 25
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
• KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 22
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 22
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 22
• 239000007864 aqueous solution Substances 0.000 description 22
• 238000001819 mass spectrum Methods 0.000 description 22
• 229910052700 potassium Inorganic materials 0.000 description 22
• 239000011591 potassium Substances 0.000 description 22
• 239000011734 sodium Substances 0.000 description 22
• 239000012153 distilled water Substances 0.000 description 21
• 230000008018 melting Effects 0.000 description 21
• 238000002844 melting Methods 0.000 description 21
• 239000012074 organic phase Substances 0.000 description 20
• 239000012266 salt solution Substances 0.000 description 20
• 229910052708 sodium Inorganic materials 0.000 description 20
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 19
• 238000009835 boiling Methods 0.000 description 19
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 19
• 238000001556 precipitation Methods 0.000 description 19
• 239000012312 sodium hydride Substances 0.000 description 19
• 229910000104 sodium hydride Inorganic materials 0.000 description 19
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 17
• 239000002585 base Substances 0.000 description 17
• GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 17
• 238000010828 elution Methods 0.000 description 16
• 239000000706 filtrate Substances 0.000 description 16
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 16
• 239000012071 phase Substances 0.000 description 15
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 15
• 241000282414 Homo sapiens Species 0.000 description 14
• 235000017557 sodium bicarbonate Nutrition 0.000 description 14
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
• 210000004027 cell Anatomy 0.000 description 13
• 239000002244 precipitate Substances 0.000 description 13
• 230000003197 catalytic effect Effects 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• 230000000694 effects Effects 0.000 description 12
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
• 239000012298 atmosphere Substances 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 239000012230 colorless oil Substances 0.000 description 11
• 238000003756 stirring Methods 0.000 description 11
• 238000000605 extraction Methods 0.000 description 10
• 239000010410 layer Substances 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• 239000002253 acid Substances 0.000 description 9
• 239000012043 crude product Substances 0.000 description 9
• 239000012442 inert solvent Substances 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 230000005526 G1 to G0 transition Effects 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 239000005557 antagonist Substances 0.000 description 8
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
• 239000012044 organic layer Substances 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• 201000011510 cancer Diseases 0.000 description 7
• PEIWEWAFPIVFLO-UHFFFAOYSA-N ethyl 2-[2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound C1=CC=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 PEIWEWAFPIVFLO-UHFFFAOYSA-N 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 206010028980 Neoplasm Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
• 229920002472 Starch Polymers 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 238000001704 evaporation Methods 0.000 description 6
• 230000008020 evaporation Effects 0.000 description 6
• 239000012458 free base Substances 0.000 description 6
• 238000004108 freeze drying Methods 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 229910052938 sodium sulfate Inorganic materials 0.000 description 6
• 235000011152 sodium sulphate Nutrition 0.000 description 6
• 239000008107 starch Substances 0.000 description 6
• 235000019698 starch Nutrition 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 238000005406 washing Methods 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
• 208000035150 Hypercholesterolemia Diseases 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 238000001816 cooling Methods 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 239000000155 melt Substances 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 150000003254 radicals Chemical class 0.000 description 5
• 238000006722 reduction reaction Methods 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
• WQZDEYIYDUDRHM-UHFFFAOYSA-N 2-(3-ethoxy-2-methyl-3-oxoprop-1-enyl)benzoic acid Chemical compound CCOC(=O)C(C)=CC1=CC=CC=C1C(O)=O WQZDEYIYDUDRHM-UHFFFAOYSA-N 0.000 description 4
• XEFXQIBENKOFCP-UHFFFAOYSA-N 2-benzyl-3-hydroxy-3h-isoindol-1-one Chemical compound O=C1C2=CC=CC=C2C(O)N1CC1=CC=CC=C1 XEFXQIBENKOFCP-UHFFFAOYSA-N 0.000 description 4
• ZBCQTCLALHBYRC-UHFFFAOYSA-N 2-ethyl-3-hydroxy-3h-isoindol-1-one Chemical compound C1=CC=C2C(=O)N(CC)C(O)C2=C1 ZBCQTCLALHBYRC-UHFFFAOYSA-N 0.000 description 4
• WAKQJXPJVPXAES-UHFFFAOYSA-N 3-hydroxy-2-propan-2-yl-3h-isoindol-1-one Chemical compound C1=CC=C2C(=O)N(C(C)C)C(O)C2=C1 WAKQJXPJVPXAES-UHFFFAOYSA-N 0.000 description 4
• JJFIJEHIMOGTAS-UHFFFAOYSA-N 3-hydroxy-5-methyl-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound CC1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1 JJFIJEHIMOGTAS-UHFFFAOYSA-N 0.000 description 4
• RCNVWPZXBAGJQE-UHFFFAOYSA-N 4-benzylisoindole-1,3-dione Chemical compound O=C1NC(=O)C2=C1C=CC=C2CC1=CC=CC=C1 RCNVWPZXBAGJQE-UHFFFAOYSA-N 0.000 description 4
• AKAAHMXNWDUFTD-UHFFFAOYSA-N 5-(trifluoromethyl)-2-benzofuran-1,3-dione Chemical compound FC(F)(F)C1=CC=C2C(=O)OC(=O)C2=C1 AKAAHMXNWDUFTD-UHFFFAOYSA-N 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• 208000031226 Hyperlipidaemia Diseases 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 150000008064 anhydrides Chemical class 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 239000012141 concentrate Substances 0.000 description 4
• 235000008504 concentrate Nutrition 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
• 239000006196 drop Substances 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• YPPWOULNTSHJTA-UHFFFAOYSA-N ethyl 2-(2-benzyl-3-oxo-1h-isoindol-1-yl)acetate Chemical compound O=C1C2=CC=CC=C2C(CC(=O)OCC)N1CC1=CC=CC=C1 YPPWOULNTSHJTA-UHFFFAOYSA-N 0.000 description 4
• WUKDBWXBOTZTIR-UHFFFAOYSA-N ethyl 2-(3-oxo-2-propyl-1h-isoindol-1-yl)acetate Chemical compound C1=CC=C2C(=O)N(CCC)C(CC(=O)OCC)C2=C1 WUKDBWXBOTZTIR-UHFFFAOYSA-N 0.000 description 4
• KTHHQKIYHJXBET-UHFFFAOYSA-N ethyl 2-[2-(2-methylpropyl)-3-oxo-5-propan-2-yloxy-1h-isoindol-1-yl]acetate Chemical compound CC(C)OC1=CC=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 KTHHQKIYHJXBET-UHFFFAOYSA-N 0.000 description 4
• YWRHQTNNGGJRRJ-UHFFFAOYSA-N ethyl 2-[7-fluoro-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound C1=CC(F)=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 YWRHQTNNGGJRRJ-UHFFFAOYSA-N 0.000 description 4
• XHINFNFATRZSQR-UHFFFAOYSA-N ethyl 3-[2-(butylcarbamoyl)phenyl]-2-methylprop-2-enoate Chemical compound CCCCNC(=O)C1=CC=CC=C1C=C(C)C(=O)OCC XHINFNFATRZSQR-UHFFFAOYSA-N 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000001681 protective effect Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 239000012557 regeneration buffer Substances 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 239000011534 wash buffer Substances 0.000 description 4
• WLTVJCASEKGOKT-UHFFFAOYSA-N 2-(cyclopropylmethyl)-3-hydroxy-3h-isoindol-1-one Chemical compound O=C1C2=CC=CC=C2C(O)N1CC1CC1 WLTVJCASEKGOKT-UHFFFAOYSA-N 0.000 description 3
• SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 3
• RVQUYEXALIBNEG-UHFFFAOYSA-N 3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound C1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1 RVQUYEXALIBNEG-UHFFFAOYSA-N 0.000 description 3
• UCEXMNLISKKYAE-UHFFFAOYSA-N 3-hydroxy-2-methyl-3h-isoindol-1-one Chemical compound C1=CC=C2C(=O)N(C)C(O)C2=C1 UCEXMNLISKKYAE-UHFFFAOYSA-N 0.000 description 3
• JAXAAVLDJKVGBI-UHFFFAOYSA-N 4-(2-methylpropyl)isoindole-1,3-dione Chemical compound CC(C)CC1=CC=CC2=C1C(=O)NC2=O JAXAAVLDJKVGBI-UHFFFAOYSA-N 0.000 description 3
• VNLYHYHJIXGBFX-UHFFFAOYSA-N 4-(trifluoromethyl)phthalic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1C(O)=O VNLYHYHJIXGBFX-UHFFFAOYSA-N 0.000 description 3
• KXSHNVJERWAQNY-UHFFFAOYSA-N 5-bromo-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound BrC1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1 KXSHNVJERWAQNY-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
• LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 230000003178 anti-diabetic effect Effects 0.000 description 3
• 239000006286 aqueous extract Substances 0.000 description 3
• 230000003143 atherosclerotic effect Effects 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 235000012000 cholesterol Nutrition 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 208000037765 diseases and disorders Diseases 0.000 description 3
• XEWVSUVYIIQHTE-UHFFFAOYSA-N ethyl 2-(2-ethyl-3-oxo-1h-isoindol-1-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OCC)N(CC)C(=O)C2=C1 XEWVSUVYIIQHTE-UHFFFAOYSA-N 0.000 description 3
• QFKUQQFSYPCODB-UHFFFAOYSA-N ethyl 2-(2-methyl-3-oxo-1h-isoindol-1-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OCC)N(C)C(=O)C2=C1 QFKUQQFSYPCODB-UHFFFAOYSA-N 0.000 description 3
• WCJDCTJTFVVWGR-UHFFFAOYSA-N ethyl 2-[2-(cyclopropylmethyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound O=C1C2=CC=CC=C2C(CC(=O)OCC)N1CC1CC1 WCJDCTJTFVVWGR-UHFFFAOYSA-N 0.000 description 3
• LMWLTSUOZGCLAK-UHFFFAOYSA-N ethyl 2-[4-methyl-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound C1=CC=C(C)C2=C1C(CC(=O)OCC)N(CC(C)C)C2=O LMWLTSUOZGCLAK-UHFFFAOYSA-N 0.000 description 3
• ZNCOBNBZFWVLGE-UHFFFAOYSA-N ethyl 2-[5-methyl-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound CC1=CC=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 ZNCOBNBZFWVLGE-UHFFFAOYSA-N 0.000 description 3
• DKVRHDXURRBCQJ-UHFFFAOYSA-N ethyl 2-methyl-3-[2-(2-methylpropylcarbamoyl)phenyl]prop-2-enoate Chemical compound CCOC(=O)C(C)=CC1=CC=CC=C1C(=O)NCC(C)C DKVRHDXURRBCQJ-UHFFFAOYSA-N 0.000 description 3
• 239000003925 fat Substances 0.000 description 3
• 235000019197 fats Nutrition 0.000 description 3
• 239000007850 fluorescent dye Substances 0.000 description 3
• 125000001153 fluoro group Chemical group F* 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 239000003701 inert diluent Substances 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 239000012160 loading buffer Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 238000005191 phase separation Methods 0.000 description 3
• 230000009257 reactivity Effects 0.000 description 3
• 239000013049 sediment Substances 0.000 description 3
• 125000004434 sulfur atom Chemical group 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 235000015112 vegetable and seed oil Nutrition 0.000 description 3
• 239000008158 vegetable oil Substances 0.000 description 3
• DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
• OQOGEOLRYAOSKO-UHFFFAOYSA-N 1,1-dichloro-1-nitroethane Chemical compound CC(Cl)(Cl)[N+]([O-])=O OQOGEOLRYAOSKO-UHFFFAOYSA-N 0.000 description 2
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• NGVVTWHRVRWVNT-UHFFFAOYSA-N 2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)isoindole-1,3-dione Chemical compound C1=C(C(F)(F)F)C=C2C(=O)N(CC(F)(F)F)C(=O)C2=C1 NGVVTWHRVRWVNT-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
• VDIVKYADOJKEQI-UHFFFAOYSA-N 3-hydroxy-2-(2-methylpropyl)-5-(trifluoromethyl)-3h-isoindol-1-one Chemical compound FC(F)(F)C1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1 VDIVKYADOJKEQI-UHFFFAOYSA-N 0.000 description 2
• PWQYEAOEHMEKPM-UHFFFAOYSA-N 3-hydroxy-2-(2-methylpropyl)-5-propan-2-yloxy-3h-isoindol-1-one Chemical compound CC(C)OC1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1 PWQYEAOEHMEKPM-UHFFFAOYSA-N 0.000 description 2
• IRTFQHFOWRLQEI-UHFFFAOYSA-N 3-hydroxy-2-propyl-3h-isoindol-1-one Chemical compound C1=CC=C2C(=O)N(CCC)C(O)C2=C1 IRTFQHFOWRLQEI-UHFFFAOYSA-N 0.000 description 2
• LLWXFNCMIJWRNB-UHFFFAOYSA-N 3-hydroxy-4-methyl-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound O=C1N(CC(C)C)C(O)C2=C1C=CC=C2C LLWXFNCMIJWRNB-UHFFFAOYSA-N 0.000 description 2
• PIWPGPPVKGVIGM-UHFFFAOYSA-N 3-hydroxy-5-methylsulfonyl-2-(2,2,2-trifluoroethyl)-3h-isoindol-1-one Chemical compound CS(=O)(=O)C1=CC=C2C(=O)N(CC(F)(F)F)C(O)C2=C1 PIWPGPPVKGVIGM-UHFFFAOYSA-N 0.000 description 2
• DBTDVGCSXLIXFC-UHFFFAOYSA-N 3-hydroxy-6-methyl-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound C1=C(C)C=C2C(=O)N(CC(C)C)C(O)C2=C1 DBTDVGCSXLIXFC-UHFFFAOYSA-N 0.000 description 2
• BZRUVOPKPLIQRV-UHFFFAOYSA-N 4,7-difluoro-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound FC1=CC=C(F)C2=C1C(=O)N(CC(C)C)C2O BZRUVOPKPLIQRV-UHFFFAOYSA-N 0.000 description 2
• BTTRMCQEPDPCPA-UHFFFAOYSA-N 4-chlorophthalic anhydride Chemical compound ClC1=CC=C2C(=O)OC(=O)C2=C1 BTTRMCQEPDPCPA-UHFFFAOYSA-N 0.000 description 2
• KUDSWYWYOFRTOG-UHFFFAOYSA-N 4-fluoro-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound O=C1N(CC(C)C)C(O)C2=C1C=CC=C2F KUDSWYWYOFRTOG-UHFFFAOYSA-N 0.000 description 2
• DSZIBQSBTYIJHM-UHFFFAOYSA-N 5-chloro-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound ClC1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1 DSZIBQSBTYIJHM-UHFFFAOYSA-N 0.000 description 2
• BGJNRQSGJHVURK-UHFFFAOYSA-N 5-chloroisoindole-1,3-dione Chemical compound ClC1=CC=C2C(=O)NC(=O)C2=C1 BGJNRQSGJHVURK-UHFFFAOYSA-N 0.000 description 2
• BZULLMJPYAWUBF-UHFFFAOYSA-N 5-methylsulfanyl-2-(2,2,2-trifluoroethyl)isoindole-1,3-dione Chemical compound CSC1=CC=C2C(=O)N(CC(F)(F)F)C(=O)C2=C1 BZULLMJPYAWUBF-UHFFFAOYSA-N 0.000 description 2
• FHDAAZRNCSFQIH-UHFFFAOYSA-N 5-tert-butyl-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound CC(C)(C)C1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1 FHDAAZRNCSFQIH-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• IUEQRUCSQKGUNO-UHFFFAOYSA-N C(C)OP(=O)(OCC)CC(=O)O.C(C)OCC Chemical compound C(C)OP(=O)(OCC)CC(=O)O.C(C)OCC IUEQRUCSQKGUNO-UHFFFAOYSA-N 0.000 description 2
• 101100322308 Caenorhabditis elegans gar-1 gene Proteins 0.000 description 2
• 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 235000019743 Choline chloride Nutrition 0.000 description 2
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 108090001030 Lipoproteins Proteins 0.000 description 2
• 102000004895 Lipoproteins Human genes 0.000 description 2
• CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
• UCTLHLZWKJIXJI-LXIBVNSESA-N [(3s,8r,9s,10r,13s,14s)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(Cl)=C(C=O)C[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 UCTLHLZWKJIXJI-LXIBVNSESA-N 0.000 description 2
• BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
• 229960000571 acetazolamide Drugs 0.000 description 2
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
• 239000012346 acetyl chloride Substances 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000006978 adaptation Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 150000001350 alkyl halides Chemical class 0.000 description 2
• 235000011114 ammonium hydroxide Nutrition 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 229940124599 anti-inflammatory drug Drugs 0.000 description 2
• 230000002337 anti-port Effects 0.000 description 2
• 239000003146 anticoagulant agent Substances 0.000 description 2
• 239000003472 antidiabetic agent Substances 0.000 description 2
• 230000036523 atherogenesis Effects 0.000 description 2
• 230000000923 atherogenic effect Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000001772 blood platelet Anatomy 0.000 description 2
• 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
• 229960003178 choline chloride Drugs 0.000 description 2
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 230000008034 disappearance Effects 0.000 description 2
• 239000002934 diuretic Substances 0.000 description 2
• 229940030606 diuretics Drugs 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000002651 drug therapy Methods 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• YUTVFVAWFMQKDI-UHFFFAOYSA-N ethyl 2-(3-oxo-2-propan-2-yl-1h-isoindol-1-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OCC)N(C(C)C)C(=O)C2=C1 YUTVFVAWFMQKDI-UHFFFAOYSA-N 0.000 description 2
• COWCYIILKHCRSN-UHFFFAOYSA-N ethyl 2-[4,7-difluoro-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound FC1=CC=C(F)C2=C1C(CC(=O)OCC)N(CC(C)C)C2=O COWCYIILKHCRSN-UHFFFAOYSA-N 0.000 description 2
• FGXRLXZIVYOTOY-UHFFFAOYSA-N ethyl 2-[5,6-dichloro-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound ClC1=C(Cl)C=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 FGXRLXZIVYOTOY-UHFFFAOYSA-N 0.000 description 2
• JDBJKPYXWQMQNS-UHFFFAOYSA-N ethyl 2-[5-bromo-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound BrC1=CC=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 JDBJKPYXWQMQNS-UHFFFAOYSA-N 0.000 description 2
• QYCAQXQGRMAARM-UHFFFAOYSA-N ethyl 2-[6-methyl-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound C1=C(C)C=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 QYCAQXQGRMAARM-UHFFFAOYSA-N 0.000 description 2
• 238000005755 formation reaction Methods 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 229960004580 glibenclamide Drugs 0.000 description 2
• WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
• 229960004346 glimepiride Drugs 0.000 description 2
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
• 229960000789 guanidine hydrochloride Drugs 0.000 description 2
• 230000000055 hyoplipidemic effect Effects 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 238000002329 infrared spectrum Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 230000012105 intracellular pH reduction Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
• NGGXACLSAZXJGM-UHFFFAOYSA-N n-(diaminomethylidene)acetamide Chemical compound CC(=O)N=C(N)N NGGXACLSAZXJGM-UHFFFAOYSA-N 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 229930014626 natural product Natural products 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 230000020477 pH reduction Effects 0.000 description 2
• 125000005543 phthalimide group Chemical class 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 239000005495 thyroid hormone Substances 0.000 description 2
• 229940036555 thyroid hormone Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
• WOMFWGRSYUKSSE-UHFFFAOYSA-N (1,3-dioxo-2-benzofuran-5-yl) acetate Chemical compound CC(=O)OC1=CC=C2C(=O)OC(=O)C2=C1 WOMFWGRSYUKSSE-UHFFFAOYSA-N 0.000 description 1
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
• ULIYQAUQKZDZOX-UHFFFAOYSA-N 1,1,1-trifluoro-3-iodopropane Chemical compound FC(F)(F)CCI ULIYQAUQKZDZOX-UHFFFAOYSA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• MHURAIRPFPJGAT-UHFFFAOYSA-N 1-methylpyrrolidin-2-one Chemical compound CN1CCCC1=O.CN1CCCC1=O.CN1CCCC1=O MHURAIRPFPJGAT-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• DZGMFITYAJIDHR-UHFFFAOYSA-N 2,3-dihydro-1h-indene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)N)CCC2=C1 DZGMFITYAJIDHR-UHFFFAOYSA-N 0.000 description 1
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
• QORUQTIDCKMSIX-UHFFFAOYSA-N 2-(cyclopropylmethyl)-3-(2-imidazol-1-yl-2-oxoethyl)-5-(trifluoromethyl)-3h-isoindol-1-one Chemical compound C1=CN=CN1C(=O)CC1C2=CC(C(F)(F)F)=CC=C2C(=O)N1CC1CC1 QORUQTIDCKMSIX-UHFFFAOYSA-N 0.000 description 1
• LQTKVWSJMFNXNU-UHFFFAOYSA-N 2-[1-[1-(diaminomethylideneamino)-1-oxopropan-2-yl]-3-oxo-1h-isoindol-2-yl]acetic acid Chemical compound C1=CC=C2C(C(C)C(=O)NC(N)=N)N(CC(O)=O)C(=O)C2=C1 LQTKVWSJMFNXNU-UHFFFAOYSA-N 0.000 description 1
• WXSGWTZQDIECHH-UHFFFAOYSA-N 2-[2-(cyclopropylmethyl)-3-oxo-6-(trifluoromethyl)-1h-isoindol-1-yl]acetic acid Chemical compound O=C1C2=CC=C(C(F)(F)F)C=C2C(CC(=O)O)N1CC1CC1 WXSGWTZQDIECHH-UHFFFAOYSA-N 0.000 description 1
• BEZWCAPOQKZQSJ-UHFFFAOYSA-N 2-[5,6-dichloro-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetic acid Chemical compound ClC1=C(Cl)C=C2C(=O)N(CC(C)C)C(CC(O)=O)C2=C1 BEZWCAPOQKZQSJ-UHFFFAOYSA-N 0.000 description 1
• NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
• DYNFCHNNOHNJFG-UHFFFAOYSA-N 2-formylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C=O DYNFCHNNOHNJFG-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• BBAJPPCDTUZGNX-UHFFFAOYSA-N 3-hydroxy-2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)-3h-isoindol-1-one Chemical compound C1=C(C(F)(F)F)C=C2C(O)N(CC(F)(F)F)C(=O)C2=C1 BBAJPPCDTUZGNX-UHFFFAOYSA-N 0.000 description 1
• VYEWZIGLODHOPI-UHFFFAOYSA-N 3-hydroxy-2-(2,2,2-trifluoroethyl)-6-(trifluoromethyl)-3h-isoindol-1-one Chemical compound FC(F)(F)C1=CC=C2C(O)N(CC(F)(F)F)C(=O)C2=C1 VYEWZIGLODHOPI-UHFFFAOYSA-N 0.000 description 1
• USSSPRHMDCNEIO-UHFFFAOYSA-N 3-hydroxy-2-(2-methylpropyl)-5-propan-2-yloxy-3H-isoindol-1-one Chemical compound CC(C)OC1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1.CC(C)OC1=CC=C2C(=O)N(CC(C)C)C(O)C2=C1 USSSPRHMDCNEIO-UHFFFAOYSA-N 0.000 description 1
• ZWRMRXIGEWRMJB-UHFFFAOYSA-N 3-hydroxy-7-methyl-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound C1=CC(C)=C2C(=O)N(CC(C)C)C(O)C2=C1 ZWRMRXIGEWRMJB-UHFFFAOYSA-N 0.000 description 1
• AVLRPSLTCCWJKC-UHFFFAOYSA-N 4,7-difluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C(F)C2=C1C(=O)OC2=O AVLRPSLTCCWJKC-UHFFFAOYSA-N 0.000 description 1
• GXHIIKQHLSFWBG-UHFFFAOYSA-N 4,7-difluoro-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound FC1=CC=C(F)C2=C1C(=O)N(CC(C)C)C2O.FC1=CC=C(F)C2=C1C(=O)N(CC(C)C)C2O GXHIIKQHLSFWBG-UHFFFAOYSA-N 0.000 description 1
• DANLZOIRUUHIIX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C1=CC=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F DANLZOIRUUHIIX-UHFFFAOYSA-N 0.000 description 1
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
• GCAIYLBJUFLNDP-UHFFFAOYSA-N 4-acetyloxyphthalic acid Chemical compound CC(=O)OC1=CC=C(C(O)=O)C(C(O)=O)=C1 GCAIYLBJUFLNDP-UHFFFAOYSA-N 0.000 description 1
• QQXVZGWCVOCPDR-UHFFFAOYSA-N 4-ethylisoindole-1,3-dione Chemical compound CCC1=CC=CC2=C1C(=O)NC2=O QQXVZGWCVOCPDR-UHFFFAOYSA-N 0.000 description 1
• WWJAZKZLSDRAIV-UHFFFAOYSA-N 4-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=CC2=C1C(=O)OC2=O WWJAZKZLSDRAIV-UHFFFAOYSA-N 0.000 description 1
• PFPBRMZWMIHBII-UHFFFAOYSA-N 4-fluoro-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound O=C1N(CC(C)C)C(O)C2=C1C=CC=C2F.O=C1N(CC(C)C)C(O)C2=C1C=CC=C2F PFPBRMZWMIHBII-UHFFFAOYSA-N 0.000 description 1
• TWWAWPHAOPTQEU-UHFFFAOYSA-N 4-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=CC2=C1C(=O)OC2=O TWWAWPHAOPTQEU-UHFFFAOYSA-N 0.000 description 1
• ABCGRFHYOYXEJV-UHFFFAOYSA-N 4-methylisoindole-1,3-dione Chemical compound CC1=CC=CC2=C1C(=O)NC2=O ABCGRFHYOYXEJV-UHFFFAOYSA-N 0.000 description 1
• DCZRUPDDJIFAAU-UHFFFAOYSA-N 4-propan-2-ylisoindole-1,3-dione Chemical compound CC(C)C1=CC=CC2=C1C(=O)NC2=O DCZRUPDDJIFAAU-UHFFFAOYSA-N 0.000 description 1
• VNCXFTKLWWHXSB-UHFFFAOYSA-N 4-propylisoindole-1,3-dione Chemical compound CCCC1=CC=CC2=C1C(=O)NC2=O VNCXFTKLWWHXSB-UHFFFAOYSA-N 0.000 description 1
• FWFOQFDPOWAVCE-UHFFFAOYSA-N 5,6-dichloro-2-(2-methylpropyl)isoindole-1,3-dione Chemical compound ClC1=C(Cl)C=C2C(=O)N(CC(C)C)C(=O)C2=C1 FWFOQFDPOWAVCE-UHFFFAOYSA-N 0.000 description 1
• ULSOWUBMELTORB-UHFFFAOYSA-N 5,6-dichloro-2-benzofuran-1,3-dione Chemical compound C1=C(Cl)C(Cl)=CC2=C1C(=O)OC2=O ULSOWUBMELTORB-UHFFFAOYSA-N 0.000 description 1
• GDKVRIVGAHXAPA-UHFFFAOYSA-N 5,6-dichloro-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound ClC1=C(Cl)C=C2C(=O)N(CC(C)C)C(O)C2=C1.ClC1=C(Cl)C=C2C(=O)N(CC(C)C)C(O)C2=C1 GDKVRIVGAHXAPA-UHFFFAOYSA-N 0.000 description 1
• AWDNCKOMUJDOCM-UHFFFAOYSA-N 5,6-dichloro-3-hydroxy-2-(2-methylpropyl)-3h-isoindol-1-one Chemical compound ClC1=C(Cl)C=C2C(=O)N(CC(C)C)C(O)C2=C1 AWDNCKOMUJDOCM-UHFFFAOYSA-N 0.000 description 1
• BCKVHOUUJMYIAN-UHFFFAOYSA-N 5-bromo-2-benzofuran-1,3-dione Chemical compound BrC1=CC=C2C(=O)OC(=O)C2=C1 BCKVHOUUJMYIAN-UHFFFAOYSA-N 0.000 description 1
• MYQFTWFNXXYHTP-UHFFFAOYSA-N 5-chloro-2-(2,2,2-trifluoroethyl)isoindole-1,3-dione Chemical compound C1=C(Cl)C=C2C(=O)N(CC(F)(F)F)C(=O)C2=C1 MYQFTWFNXXYHTP-UHFFFAOYSA-N 0.000 description 1
• JTRZVSBRGHDZLY-UHFFFAOYSA-N 5-chloro-2-(cyclopropylmethyl)isoindole-1,3-dione Chemical compound O=C1C2=CC(Cl)=CC=C2C(=O)N1CC1CC1 JTRZVSBRGHDZLY-UHFFFAOYSA-N 0.000 description 1
• KUSVONSTRXHWDH-UHFFFAOYSA-N 5-hydroxy-2-(2-methylpropyl)isoindole-1,3-dione Chemical compound C1=C(O)C=C2C(=O)N(CC(C)C)C(=O)C2=C1 KUSVONSTRXHWDH-UHFFFAOYSA-N 0.000 description 1
• ZOXBWJMCXHTKNU-UHFFFAOYSA-N 5-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=C2C(=O)OC(=O)C2=C1 ZOXBWJMCXHTKNU-UHFFFAOYSA-N 0.000 description 1
• MIXSDUASSSAVDA-UHFFFAOYSA-N 5-methylsulfonyl-2-(2,2,2-trifluoroethyl)isoindole-1,3-dione Chemical compound CS(=O)(=O)C1=CC=C2C(=O)N(CC(F)(F)F)C(=O)C2=C1 MIXSDUASSSAVDA-UHFFFAOYSA-N 0.000 description 1
• JYVVDSVJVIKVOR-UHFFFAOYSA-N 5-tert-butyl-2-(2-methylpropyl)isoindole-1,3-dione Chemical compound C1=C(C(C)(C)C)C=C2C(=O)N(CC(C)C)C(=O)C2=C1 JYVVDSVJVIKVOR-UHFFFAOYSA-N 0.000 description 1
• YLJYVKLZVHWUCT-UHFFFAOYSA-N 5-tert-butyl-2-benzofuran-1,3-dione Chemical compound CC(C)(C)C1=CC=C2C(=O)OC(=O)C2=C1 YLJYVKLZVHWUCT-UHFFFAOYSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 108050000824 Angiotensin II receptor Proteins 0.000 description 1
• 101800000734 Angiotensin-1 Proteins 0.000 description 1
• 102400000344 Angiotensin-1 Human genes 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• 229940123208 Biguanide Drugs 0.000 description 1
• XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 239000002083 C09CA01 - Losartan Substances 0.000 description 1
• 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
• 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
• WYSFQGYSBXZZSU-UHFFFAOYSA-N CC1=C2C(N(C(C2=CC=C1)=O)CC(C)C)O.CC=1C=CC=C2C(N(C(C12)=O)CC(C)C)O Chemical compound CC1=C2C(N(C(C2=CC=C1)=O)CC(C)C)O.CC=1C=CC=C2C(N(C(C12)=O)CC(C)C)O WYSFQGYSBXZZSU-UHFFFAOYSA-N 0.000 description 1
• 101100436077 Caenorhabditis elegans asm-1 gene Proteins 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 102000003846 Carbonic anhydrases Human genes 0.000 description 1
• 108090000209 Carbonic anhydrases Proteins 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 206010048610 Cardiotoxicity Diseases 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• FDEQQCOTLPPCAO-UHFFFAOYSA-N Cl.OC(O)=O Chemical group Cl.OC(O)=O FDEQQCOTLPPCAO-UHFFFAOYSA-N 0.000 description 1
• 206010053398 Clonic convulsion Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 208000003890 Coronary Vasospasm Diseases 0.000 description 1
• 102000034534 Cotransporters Human genes 0.000 description 1
• 108020003264 Cotransporters Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 101000616562 Danio rerio Sonic hedgehog protein A Proteins 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014476 Elevated cholesterol Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 108010061435 Enalapril Proteins 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 102000004366 Glucosidases Human genes 0.000 description 1
• 108010056771 Glucosidases Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 108010010234 HDL Lipoproteins Proteins 0.000 description 1
• 102000015779 HDL Lipoproteins Human genes 0.000 description 1
• 229910004373 HOAc Inorganic materials 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101001090074 Homo sapiens Small nuclear protein PRAC1 Proteins 0.000 description 1
• 101000964584 Homo sapiens Zinc finger protein 160 Proteins 0.000 description 1
• 206010058558 Hypoperfusion Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 206010021137 Hypovolaemia Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• 108010007859 Lisinopril Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
• ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• SECXISVLQFMRJM-UHFFFAOYSA-N N-methyl-pyrrolidinone Natural products CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 101100204282 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Asm-1 gene Proteins 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
• 102000004257 Potassium Channel Human genes 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 229940123934 Reductase inhibitor Drugs 0.000 description 1
• 102100028255 Renin Human genes 0.000 description 1
• 108090000783 Renin Proteins 0.000 description 1
• 102000003800 Selectins Human genes 0.000 description 1
• 108090000184 Selectins Proteins 0.000 description 1
• 102100034766 Small nuclear protein PRAC1 Human genes 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 229940100389 Sulfonylurea Drugs 0.000 description 1
• 235000019486 Sunflower oil Nutrition 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 102000003938 Thromboxane Receptors Human genes 0.000 description 1
• 108090000300 Thromboxane Receptors Proteins 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
• 206010043994 Tonic convulsion Diseases 0.000 description 1
• NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
• FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
• 206010047163 Vasospasm Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 102100040815 Zinc finger protein 160 Human genes 0.000 description 1
• FCQDVLPJBLBTSM-UHFFFAOYSA-N [2-(2-methylpropyl)-3-oxo-1H-isoindol-1-yl] acetate Chemical compound C(C)(=O)OC1N(C(C2=CC=CC=C12)=O)CC(C)C FCQDVLPJBLBTSM-UHFFFAOYSA-N 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• FCOKLAMVAHWFCI-UHFFFAOYSA-N acetyloxymethoxymethyl acetate Chemical compound CC(=O)OCOCOC(C)=O FCOKLAMVAHWFCI-UHFFFAOYSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
• 229960002576 amiloride Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
• 229960000528 amlodipine Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
• 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
• 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
• 229940127003 anti-diabetic drug Drugs 0.000 description 1
• 230000003556 anti-epileptic effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000561 anti-psychotic effect Effects 0.000 description 1
• 239000003529 anticholesteremic agent Substances 0.000 description 1
• 229940127226 anticholesterol agent Drugs 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 239000003524 antilipemic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000002830 appetite depressant Substances 0.000 description 1
• 150000005840 aryl radicals Chemical class 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
• 229960004064 bumetanide Drugs 0.000 description 1
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
• 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 206010061592 cardiac fibrillation Diseases 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 230000001269 cardiogenic effect Effects 0.000 description 1
• 231100000259 cardiotoxicity Toxicity 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 238000000451 chemical ionisation Methods 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 230000002566 clonic effect Effects 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 150000001923 cyclic compounds Chemical class 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 229960004042 diazoxide Drugs 0.000 description 1
• AGANSXYIEFDATK-UHFFFAOYSA-N dichloromethane;sodium Chemical compound [Na].ClCCl AGANSXYIEFDATK-UHFFFAOYSA-N 0.000 description 1
• GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
• 235000021196 dietary intervention Nutrition 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
• 229960004166 diltiazem Drugs 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000007590 electrostatic spraying Methods 0.000 description 1
• 229960000873 enalapril Drugs 0.000 description 1
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 230000001037 epileptic effect Effects 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• UVWVUMKBHGUQHD-UHFFFAOYSA-N ethyl 2-[2-(2-methylpropyl)-3-oxo-5-(trifluoromethyl)-1h-isoindol-1-yl]acetate Chemical compound FC(F)(F)C1=CC=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 UVWVUMKBHGUQHD-UHFFFAOYSA-N 0.000 description 1
• HFRYDPLYCJXLKR-UHFFFAOYSA-N ethyl 2-[5-tert-butyl-2-(2-methylpropyl)-3-oxo-1h-isoindol-1-yl]acetate Chemical compound CC(C)(C)C1=CC=C2C(CC(=O)OCC)N(CC(C)C)C(=O)C2=C1 HFRYDPLYCJXLKR-UHFFFAOYSA-N 0.000 description 1
• XCHNZHOYIDHDJF-UHFFFAOYSA-N ethyl 2-methyl-3-[2-(propylcarbamoyl)phenyl]prop-2-enoate Chemical compound CCCNC(=O)C1=CC=CC=C1C=C(C)C(=O)OCC XCHNZHOYIDHDJF-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000002600 fibrillogenic effect Effects 0.000 description 1
• 230000003480 fibrinolytic effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000007941 film coated tablet Substances 0.000 description 1
• 238000002073 fluorescence micrograph Methods 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 229960002490 fosinopril Drugs 0.000 description 1
• 229910052730 francium Inorganic materials 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229960003883 furosemide Drugs 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000003349 gelling agent Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• DXTIKTAIYCJTII-UHFFFAOYSA-N guanidine acetate Chemical compound CC([O-])=O.NC([NH3+])=N DXTIKTAIYCJTII-UHFFFAOYSA-N 0.000 description 1
• ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000002837 heart atrium Anatomy 0.000 description 1
• 230000005986 heart dysfunction Effects 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229960002003 hydrochlorothiazide Drugs 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
• 208000021822 hypotensive Diseases 0.000 description 1
• 230000001077 hypotensive effect Effects 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 239000013067 intermediate product Substances 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
• 229960002198 irbesartan Drugs 0.000 description 1
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000005240 left ventricle Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 229960002394 lisinopril Drugs 0.000 description 1
• RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 210000000210 loop of henle Anatomy 0.000 description 1
• 229960004773 losartan Drugs 0.000 description 1
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000014380 magnesium carbonate Nutrition 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• 235000012245 magnesium oxide Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229950004994 meglitinide Drugs 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000004066 metabolic change Effects 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
• 229960002237 metoprolol Drugs 0.000 description 1
• 238000005497 microtitration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229960003632 minoxidil Drugs 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000003020 moisturizing effect Effects 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 229960001597 nifedipine Drugs 0.000 description 1
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
• 229950000973 omapatrilat Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 231100000255 pathogenic effect Toxicity 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 150000003022 phthalic acids Chemical class 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 229960001085 piretanide Drugs 0.000 description 1
• 229960005483 polythiazide Drugs 0.000 description 1
• 229920000046 polythiazide Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 108020001213 potassium channel Proteins 0.000 description 1
• 239000004036 potassium channel stimulating agent Substances 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000009993 protective function Effects 0.000 description 1
• 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 230000009103 reabsorption Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000031844 regulation of cellular pH Effects 0.000 description 1
• 201000002793 renal fibrosis Diseases 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 229960002052 salbutamol Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
• 229960002256 spironolactone Drugs 0.000 description 1
• SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
• 229950001870 spizofurone Drugs 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000002600 sunflower oil Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 239000005458 thiazide-like diuretic Substances 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 230000002537 thrombolytic effect Effects 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 239000010936 titanium Substances 0.000 description 1
• 229910052719 titanium Inorganic materials 0.000 description 1
• OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
• 229960005371 tolbutamide Drugs 0.000 description 1
• 230000001256 tonic effect Effects 0.000 description 1
• 229960005461 torasemide Drugs 0.000 description 1
• 229960001288 triamterene Drugs 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
• IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 229960004699 valsartan Drugs 0.000 description 1
• SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
• 239000002966 varnish Substances 0.000 description 1
• 231100000216 vascular lesion Toxicity 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 229960001722 verapamil Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229940045860 white wax Drugs 0.000 description 1